Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. The Breast 66:15–23. https://doi.org/10.1016/j.breast.2022.08.010

Article  PubMed  PubMed Central  Google Scholar 

Vučković L, Klisic A, Raonić J, Vućinić J (2021) Comparative study of immunohistochemical determination of breast cancer molecular subtypes on core biopsy and surgical specimens. Eur Rev Med Pharmacol Sci 25:3990–3996. https://doi.org/10.26355/eurrev_202106_26039

Article  PubMed  Google Scholar 

Hammerl D, Smid M, Timmermans AM, Sleijfer S, Martens JWM, Debets R (2018) Breast cancer genomics and immuno-oncological markers to guide immune therapies. Semin Cancer Biol 52:178–188. https://doi.org/10.1016/j.semcancer.2017.11.003

Article  CAS  PubMed  Google Scholar 

Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321:288–300. https://doi.org/10.1001/JAMA.2018.19323

Article  CAS  PubMed  Google Scholar 

Kerr AJ, Dodwell D, McGale P, Holt F, Duane F, Mannu G et al (2022) Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treat Rev 105:102375. https://doi.org/10.1016/j.ctrv.2022.102375

Article  CAS  PubMed  Google Scholar 

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529–1541. https://doi.org/10.1056/nejmoa2028485

Article  CAS  PubMed  Google Scholar 

Nagayama A, Vidula N, Ellisen L, Bardia A (2020) Novel antibody–drug conjugates for triple negative breast cancer. Ther Adv Med Oncol 12:175883592091598. https://doi.org/10.1177/1758835920915980

Article  CAS  Google Scholar 

Rivera E, Gomez H (2010) Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 12:S2. https://doi.org/10.1186/bcr2573

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prihantono FM (2021) Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it? Ann Med Surg 70:102793. https://doi.org/10.1016/J.AMSU.2021.102793

Article  CAS  Google Scholar 

Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA et al (2001) Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20:1300–1306. https://doi.org/10.1038/sj.onc.1204235

Article  CAS  PubMed  Google Scholar 

Lin Y, Zhong Y, Guan H, Zhang X, Sun Q (2012) CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. J Exp Clin Cancer Res 31:59. https://doi.org/10.1186/1756-9966-31-59

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tudoran O, Soritau O, Balacescu L, Visan S, Barbos O, Cojocneanu-Petric R et al (2015) Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells. Mol Cell Biochem 409:163–176. https://doi.org/10.1007/s11010-015-2522-z

Article  CAS  PubMed  Google Scholar 

Gooding AJ, Schiemann WP (2020) Epithelial-mesenchymal transition programs and cancer stem cell phenotypes: mediators of breast cancer therapy resistance. Mol Cancer Res 18:1257–1270. https://doi.org/10.1158/1541-7786.MCR-20-0067

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31:539–544. https://doi.org/10.1038/nbt.2576

Article  CAS  PubMed  Google Scholar 

Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan C-L et al (2018) Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun 9:2897. https://doi.org/10.1038/s41467-018-05220-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Margaryan NV, Seftor EA, Seftor REB, Hendrix MJC (2017) Targeting the stem cell properties of adult breast cancer cells: using combinatorial strategies to overcome drug resistance. Curr Mol Biol Rep 3:159–164. https://doi.org/10.1007/s40610-017-0067-5

Article  PubMed  PubMed Central  Google Scholar 

Thirusangu P, Ray U, Sarkar Bhattacharya S, Oien DB, Jin L, Staub J et al (2022) PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma. Oncogene 41:4003–4017. https://doi.org/10.1038/s41388-022-02391-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stevens LE, Peluffo G, Qiu X, Temko D, Fassl A, Li Z et al (2023) JAK–STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states. Cancer Res 83:264–284. https://doi.org/10.1158/0008-5472.CAN-22-0423

Article  CAS  PubMed  Google Scholar 

Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD et al (2012) Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18:869–881. https://doi.org/10.1158/1078-0432.CCR-11-2188

Article  CAS  PubMed  Google Scholar 

Lee HE, Kim JH, Kim YJ, Choi SY, Kim S-W, Kang E et al (2011) An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 104:1730–1738. https://doi.org/10.1038/bjc.2011.159

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ismaeel GL, Abdul-Hussein AH, Qasim HM, Abed NK, Jalil AT, Suleiman AA et al (2023) Therapeutic targeting of dormant cancer stem cells in solid tumors. Gene Rep 30:101717. https://doi.org/10.1016/j.genrep.2022.101717

Article  CAS  Google Scholar 

Tang B, Raviv A, Esposito D, Flanders KC, Daniel C, Nghiem BT et al (2015) A flexible reporter system for direct observation and isolation of cancer stem cells. Stem Cell Rep 4:155–169. https://doi.org/10.1016/j.stemcr.2014.11.002

Article  Google Scholar 

Pádua D, Barros R, Amaral AL, Mesquita P, Freire AF, Sousa M et al (2020) A SOX2 reporter system identifies gastric cancer stem-like cells sensitive to monensin. Cancers 2020(12):495. https://doi.org/10.3390/CANCERS12020495

Article  Google Scholar 

Vásquez-Bochm LX, Velázquez-Paniagua M, Castro-Vázquez SS, Guerrero-Rodríguez SL, Mondragon-Peralta A, De La Fuente-Granada M et al (2019) Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug. Pharmacol Rep 71:535–544. https://doi.org/10.1016/j.pharep.2019.02.011

Article  CAS  PubMed  Google Scholar 

Paramanantham A, Jung E, Kim H, Jeong B, Jung J-M, Kim G et al (2021) Doxorubicin-resistant TNBC cells exhibit rapid growth with cancer stem cell-like properties and EMT phenotype, which can be transferred to parental cells through autocrine signaling. Int J Mol Sci 22:12438. https://doi.org/10.3390/ijms222212438

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng C-C, Shi L-H, Wang X-J, Wang S-X, Wan X-Q, Liu S-R et al (2018) Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Int J Oncol 53:339–348. https://doi.org/10.3892/ijo.2018.4399

Article  CAS  PubMed  Google Scholar 

Speth PAJ, van Hoesel QGCM, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15–31. https://doi.org/10.2165/00003088-198815010-00002

Article  CAS  PubMed